Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q9HF
|
|||
| Former ID |
DIB016135
|
|||
| Drug Name |
Acetylcholine
|
|||
| Synonyms |
acetylcholine; Choline acetate; O-Acetylcholine; Acetyl choline ion; Acetylcholinum; 51-84-3; (2-Acetoxyethyl)trimethylammonium; Acetyl choline cation; Choline acetate (ester); 2-(Acetyloxy)-N,N,N-trimethylethanaminium; Ach; Azetylcholin; ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; UNII-N9YNS0M02X; BRN 1764436; CHEBI:15355; Bromoacetylcholine; EINECS 200-128-9; CHEMBL667; N9YNS0M02X; [2-(acetyloxy)ethyl]trimethylazanium; Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl- (9CI); 2-acetyloxyethyl-trimethylazanium; [3H]acetylcholine; Miochol; Miochol-e
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cataract [ICD-11: 9B10; ICD-10: H26.9; ICD-9: 366] | Approved | [1], [2] | |
| Therapeutic Class |
Cardiovascular Agents
|
|||
| Company |
Novartis Pharmaceuticals Corp
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C7H16NO2+
|
|||
| Canonical SMILES |
CC(=O)OCC[N+](C)(C)C
|
|||
| InChI |
1S/C7H16NO2/c1-7(9)10-6-5-8(2,3)4/h5-6H2,1-4H3/q+1
|
|||
| InChIKey |
OIPILFWXSMYKGL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 51-84-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
2096, 5093, 590084, 842105, 4841588, 4841589, 7885682, 7978526, 8145821, 8150495, 11109642, 11335861, 11361100, 11362796, 11365358, 11367920, 11371392, 11373691, 11376082, 11462072, 11484932, 11489074, 11490102, 11491951, 11493836, 12125264, 15041454, 22394665, 24438564, 26746577, 26756572, 46504484, 47365195, 47440269, 47515326, 49903095, 50100837, 50103887, 51015577, 51071830, 53790976, 53812333, 53812666, 57320023, 84970650, 85209498, 92308690, 103061050, 104234160, 104294102
|
|||
| ChEBI ID |
CHEBI:15355
|
|||
| ADReCS Drug ID | BADD_D00030 ; BADD_D00031 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Muscarinic acetylcholine receptor (CHRM) | Target Info | Agonist | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Cholinergic synapse | ||||
| Regulation of actin cytoskeleton | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Muscarinic acetylcholine receptors | |||
| Acetylcholine regulates insulin secretion | ||||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| Regulation of Actin Cytoskeleton | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Secretion of Hydrochloric Acid in Parietal Cells | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 294). | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.